Page 41 - Alkermes News Today

StockNews.com upgraded shares of Alkermes (NASDAQ:ALKS – Get Rating) from a buy rating to a strong-buy rating in a research note issued to investors on Thursday morning. Several other research analysts have also weighed in on the company. Stifel Nicolaus lifted their price objective on Alkermes to $30.00 in a research report on Thursday, February […]

Alkermes (NASDAQ:ALKS – Get Rating) had its price objective increased by Mizuho from $36.00 to $37.00 in a report released on Tuesday, The Fly reports. Mizuho currently has a buy rating on the stock. A number of other equities analysts have also commented on ALKS. HC Wainwright reiterated a neutral rating and issued a $32.00 […]

An LGBTQ+ perspective on living openly and leaving alcohol behind.

Immune checkpoint inhibitor retreatment in advanced melanoma is used in clinical practice, but there is a lack of evidence to support it.

The ovarian cancer market is expected to grow significantly owing to an increase in diagnosed cases, increased awareness about the disease, increased R&D for developing new molecules, and the

A recently published study by FMI expects the global alcohol use disorder treatment market demand to augment at a 6.4% CAGR from 2023 to 2033. By the end of the said assessment period, a valuation of US$ 1300 million is expected for the market. The growing number of drug awareness campaigns, preventative programs, a...

/PRNewswire/ -- DelveInsights Ovarian Cancer Market Insights report includes a comprehensive understanding of current treatment practices, ovarian cancer...

According to a market research study published by Zion Market Research, Global Pharmaceutical Solid Dosage Contract Manufacturing Market size & share...

ALKERMES PUBLIC LIMITED COMPANY DIRECTORS REPORT AND CONSOLIDATED FINANCIAL STATEMENTS For the Financial Year Ended... | April 6, 2023

Niraparib maintenance does not improve overall survival in patients with platinum-sensitive recurrent ovarian cancer, updated data suggest.